Tamoxifen calms down the distressed PDAC stroma
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest human cancers and is associated with extensive desmoplastic changes in the tumor microenvironment. In this issue of EMBO Reports, two studies by Cortes et al identify the G-protein-coupled estrogen receptor (GPER) as an important regula...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
2019
|
| In: |
EMBO reports
Year: 2018, Volume: 20, Issue: 1 |
| ISSN: | 1469-3178 |
| DOI: | 10.15252/embr.201847334 |
| Online Access: | Verlag, Volltext: https://doi.org/10.15252/embr.201847334 Verlag: https://www.embopress.org/doi/full/10.15252/embr.201847334 
|
| Author Notes: | Maren Pein & Thordur Oskarsson |
| Summary: | Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest human cancers and is associated with extensive desmoplastic changes in the tumor microenvironment. In this issue of EMBO Reports, two studies by Cortes et al identify the G-protein-coupled estrogen receptor (GPER) as an important regulator of the PDAC-associated stroma, modulating tissue stiffness, hypoxic responses, and desmoplasia. Intriguingly, the authors find that tamoxifen, which is widely used for its antagonizing effect on nuclear estrogen receptor (ER)-positive breast cancers, acts as GPER agonist to normalize the PDAC microenvironment. The two studies thus open up new opportunities to explore tamoxifen as potential anti-stromal therapy in PDAC. |
|---|---|
| Item Description: | Published online 11 December 2018 Gesehen am 21.10.2019 |
| Physical Description: | Online Resource |
| ISSN: | 1469-3178 |
| DOI: | 10.15252/embr.201847334 |